Posted on

חדשות ביראד – יוני 2018

חוקרים יקרים,

לאחרונה הגדלנו את מערך הפיתוח העסקי, עבורכם החוקרים, עם ד”ר איריס האס  שהצטרפה  לד”ר פרנסיס שליט, סמנכ”לית פיתוח עסקי לתחום מדעי החיים והכימיה ומר נתי פישר, סמנכ”ל פיתוח עסקי לתחום המדעים המדויקים ומדעי המחשב.
צוות הפיתוח העסקי ואנוכי שוקדים על בניית אסטרטגיה עסקית ארוכת טווח הכוללת מגוון טכניקות למימושן. החל מביצוע מחקרי שוק ואיסוף מידע מודיעיני, יישום מודלים עסקיים של פיתוח עסקי, ניתוח כלכלי ניהול סיכונים. וכלה בבניית חומרים שיווקיים רלוונטיים, יצירת שיתופי פעולה אסטרטגיים וחדשנות טכנולוגית.
הצוות עושה לילות כימים בקידום יכולות המסחור של ביראד –  בניהול מו”מ מורכבים עם חברות ומשקיעים, בטיפוח קשרים עם קולגות בחברות יישום מקבילות, ובהשתתפות בימי עיון, כנסים ותערוכות על מנת לחשוף את חוקרי האוניברסיטה ואת מרכזי השירות שלה ועוד.
אתם מוזמנים לבחון את “הקולות קוראים” שבעלון זה ולפנות בכל עת לצוות הפיתוח העסקי בכל שאלה או בקשה.

חדש – מרכז מידע במיוחד בשבילכם – כל מה שחוקר צריך : למרכז המידע

שלכם,
ד”ר צביקה בן-פורת, מנכ”ל

שימו לב – תמיכה חדשה בקבצי PDF  – העיון בעמודים השונים ע”י החיצים ↑  ↓  בראש המסמך. קריאה מהנה

עלון לחוקרים - חודש יוני 2018 2

Posted on

Isotopia Company and Prof. Rachela Popovtzer of Bar-Ilan University are developing an innovative method for diagnosis and treatment of cancer

The Israeli Isotopia Company, in collaboration with Prof. Rachela Popovtzer of Bar-Ilan University, is conducting a joint study to develop a radioactive marker, based on nanoparticles, for the detection of cancer.   The goal of this research is to facilitate, for the first time, the distinction between tumors and inflammation.

The most common imaging method for diagnosing and monitoring cancer today is the positron emission tomography (PET) scan used with radioactive contrast material fluorodeoxyglucose (FDG). But FDG gives high rates of false positives, which lead to false therapeutic observations and expensive costs for health care systems. The main problem is that the test can detect not only tumors, but also inflammation, making it difficult to differentiate between cancerous growths and inflammation.

The material being developed by the researchers is a radioactive contrast agent based on nanoparticles.  In addition to identifying, imaging and tracking cancer tumors, these nanoparticles make it possible to make an unequivocal distinction between tumor and inflammation.

“The technology we are developing is significant because it will enable physicians to make a better diagnosis,” said Dr. Eli Shalom, CEO of Isotopia Molecular Imaging.  “Another advantage is that it will be used in existing PET/CT centers and rely on equipment that’s already in place,  so it’s very economical.”

Dr. Shalom said that the vision in this development is far beyond specific cancer identification.  “The method we are developing can be combined with Lu177  for therapy as well as the imaging.  This is an innovative field called Theranostics (therapy + diagnostics). In the Theranostics model, we use the same molecules and radiolabel them for imaging and therapy each time with a different isotope. “. Isotopia, which today focuses on the development of Theranostic products for prostate cancer, will be an excellent platform for bringing development to the Global market

The research is being carried out within the framework of the “Magneton” program of the “Innovation Authority” (formerly the “Bureau of the Scientist”), which funds research aimed at encouraging the transfer of technological know-how accumulated in academia for innovative industry products. Fundraising for Magneton (for Bar-Ilan University) was overseen by Birad Research and Development Company Ltd.”.

About Isotopia
Isotopia, the nuclear pharmacy with knowledge and experience in the radiochemical connection, has extensive experience in developing processes and applying them for molecular imaging. The Isotopia development team is a multidisciplinary team consisting of nuclear pharmacists, radiochemists, nuclear engineers and physicists.

The experienced Isotopia team, together with its radio-nuclear pharmacy and cyclotron facility, are a well-established platform for development. Isotopia conducts research and development initiatives in cooperation with leading medical centers and with leading research laboratories in Israel. Isotopia creates collaborations between the scientific and medical community to further develop and experiment with new markers for imaging applications and molecular therapy. Isotopia develops strategic partnerships in procurement, production and international sales of Isotopes in the manufacture of cyclotron, radio-pharmaceuticals and related molecular imaging technologies, as well as new developments in the field of radiotherapy.

About Birad – Research & Development Company Ltd. The commercializing company of Bar-Ilan University, which promotes collaborations, corporations and alliances to manage the intellectual property, and technology commercialization by creating risk and licensing, promoting scientific service agreements through the technological knowledge and infrastructure of the University for the benefit of members of the industrial community, and outsourcing services for the business sector as part of the Division of Scientific Services.

For more information: Merav Burstein. Tel: 0773643534. Merav@birad.biz

Posted on

חדשות ביראד – מאי 2018

חוקרים יקרים,

במהלך החודש שחלף השתתפו מספר חוקרים מאוניברסיטת בר-אילן במפגש סיעור מוחות לקראת התארגנות למאגד פיתוח טכנולוגיות להנדסה ולהדפסה תלת-ממדית של תאים, רקמות ואיברים.

מפגש זה הינו אחד המיזמים אותם מקדמת “הרשות לחדשנות”, שחקן מרכזי בקידום קשרים בין אקדמיה ותעשיה, שאחת ממשימותיה הוא שימור וחיזוק המובילות הטכנולוגית והתרבות היזמית בישראל והגדלת הערך הכלכלי שאלו מניבים למשק הישראלי.

צוות הפיתוח העסקי של ביראד, אשר עובד בשת”פ ישיר מול נציגי הרשות, ליווה את החוקרים החל מביצוע הפניה אליהם, רישומם למפגש, וכלה בריכוז החומרים הנדרשים והכנתם לבחינה ועיון של נציגי הרשות.

פרופ’ יובל גרעיני מהמחלקה לפיזיקה והמכון לננו טכנולוגיה וחומרים מתקדמים, הציג במפגש את מחקרו ואת מחקרם של עמיתיו : פרופ’ חגי שפייזמן, (מהמחלקה לכימיה), פרופ’ אורית שפי וד”ר עמוס שרוני (המחלקה למדעי המחשב) ופרופ’ רון גולדשטיין (הפקולטה למדעי החיים).

נציגי הרשות גילו עניין רב בתחומי המחקר שהוצגו בפניהם וציינו כי הם מעבירים את הנושאים לשלב הבא.

מפגשים מסוג זה מאפשרים היכרות ישירה ובלתי אמצעית עם החוקרים ומהווים פלטפורמה שאינה ברת תחליף ליצירת הזדמנויות בשיתופי פעולה במו”פ, בהשקעות ובקשרים מסחריים בין הגורמים השונים.

בגיליון זה כמו באחרים אנו מזמינים אתכם לקחת חלק בפרויקטים השונים שמובילה “הרשות לחדשנות”.

אני תקווה כי אתם פותחים את העלונים ומעיינים בהם.

 

שלכם,

ד”ר צביקה בן-פורת, מנכ”ל

מנכ”ל ביראד

 

Posted on

‘Good’ and ‘Bad’ Responses in Situations of Uncertainty

There are situations of uncertainty that cannot be foreseen or predicted. What do leaders do in such situations? How must process leaders behave? Leaders can be senior doctors on a medical staff that is under pressure and dealing with uncertainty, or managers leading their organizations to new business arenas or deals. Both of these operate in situations of uncertainty and they must maintain a ‘poker face’ when in contact with their staff, their employees, their clients or their suppliers and maybe even with their managers.

The expression ‘poker face’ does not imply that they must maintain a frozen, blank expression or portray apathy in the face of situations of uncertainty. It is entirely possible that the senior person’s face and expression will show faith and a desire to succeed. The idea is that the ‘poker face’ of senior executives, or their body language, will convey the proper message for that situation and not necessarily what they actually feel. Obviously, it is better if those executives feel optimistic even in situations of conflict, decrease in income or lack of success. But it is not always possible to feel that way, but yet this is what the entrepreneur, the leader or the senior executive, must convey to the people that look up to them. Controlling body language is not enough. It also requires a unique personality that has the flexibility necessary for handling events characterized by uncertainty. It is that flexibility of mind, behaviour and emotion, that enables, when any new information is received or when new findings that were formerly unknown appear, the change the method or manner of operation within seconds. A CEO, who enters into a confrontation with a client and is already planning the legal battle, must also be prepared to hold a phone conversation with the client at any given moment.

Can we determine normative responses to the question of the behaviour of people or organizations in situations of uncertainty? When analyzing the behaviour of people in situations of uncertainty, must we necessarily perceive turning a blind eye as ‘bad’ behaviour and quick action as ‘good’? Is the display of confidence by a person handling an event that is characterized by total uncertainty right or wrong behaviour?

The answers to these questions are quite complex. Because it is possible to examine them on a time basis, then there will be two answers for almost every question. We will receive the first answer immediately after the uncertainty has emerged, while the second will only be received in retrospect over time – days, weeks, months or even years. But even this answer is not enough. Because if there is an uncertainty regarding whether airplanes or meteors will fall out of the sky, does that mean that every person wishing to ensure their personal safety has to walk with a steel umbrella or helmet every time they leave the house?

Is a person who actively tries to minimize the damages of uncertainty making the right decision? Is a person who has decided to bet on a start-up that appears very promising in the beginning making the right move? In real-time the answer will be quite different than in retrospect. Usually, the tendency is to examine things on a success basis. If the protective measures taken due to the fear of failure or of some problem were effective in overcoming actual events, then the entrepreneur who initiated and took them will reap the applause. But, if the event did not occur and all of the defence systems, although fully operative, only incurred great expense – then no cries of joy will be heard.

Hundreds of millions of Dollars were invested during 1998-1999 in attempt to minimize the expected damages of ‘Bug 2000’ [The ‘Millennium Bug’]. Hundreds of millions of people around the world did not step onto elevators or travel on airplanes during the time between midnight of December 31st 1999 and 00:01 of January 1st 2000 for fear of the devastating effect this bug might have. Millions of people backed-up their computers, their bank accounts and their savings funds. What happened in the end? Nothing. Did it end this way necessarily because all of the decision makers were hysterical and acted to prevent the catastrophe or would nothing have happened whether they did anything or not? What about all of the articles written for the public which provided countless tips on how to minimize the potential damages of the bug? Two to three weeks before the end of the millennium they were extremely popular, and after the date of the millennium had passed they were addressing computer worms, other software bugs, junk mail programs and so forth. The panic, it seems, continued but changed its name. Had those who had prepared towards the bug done the right thing? Had a company who spent thousands of dollars for this purpose acted wisely? Can we today, several years after the beginning of the millennium, or more accurately, after the critical second between December 31st 1999 and January 1st 2000, judge these people who had paid so much money for an allegedly unnecessary prevention plan?

On the same note – are all investors aware of the need to check certain things before investing in a project, and once acknowledging the importance of checking, do they actually check? Do the managers of a company seeking to hire a new employee actually check the authenticity of the details in the candidate’s resume and call the references? Not always. Can there be a situation in which a person claims to own a patent, when actually they still hadn’t received formal approval from the registrar, but the investors are impressed by their abilities and explanations thus far and so they don’t actually check if they are telling the truth? Yes, and this happens much more often than one would expect.

Almost any reasonable person can provide an answer to the question “what is the right behaviour in a specific situation of uncertainty?”, but that does not mean that this person will actually act this way. The number of people having smoke detectors or fire extinguishers in their home is very low. The fact that their house can catch fire at any time or that fires occur in apartments much more frequently than once in a hundred years, does not motivate them to buy this vital equipment. Is this behaviour a form of ‘burying their head in the sand’ like an ostrich or do people just fully trust the fire department? Is this good behaviour, logical behaviour, economical behaviour? Probably not. And yet, most people still behave this way. Apparently even having very good data can still lead to making lousy decisions.

Posted on

Working in Situations of Uncertainty and Lack of Control

 

One of the more interesting topics in the discussion of the dialogue between the emotional world and business entrepreneurship, management and leadership is working in uncertain and unclear conditions. At the same time, there is also the challenging field of working in, or managing, situations we have no control over. There are, of course, people who such situations of uncertainty and no control can paralyze and render them helpless and incapable of doing anything. As opposed to that, there are people who thrive in such situations and are driven to bring out their best.

However, the question remains, can a person (whether a manager, a head of family, an engineer or doctor) always have full control over their personal and professional lives? Does the person always have full and comprehensive information about everything that happens at any given moment at every point that touches on their activities? Of course not. The world we live in changes constantly and the great availability of information floods us with data and turns some people into professional data filters. At the same time, the modern world often brings us a very high level of uncertainty. If in the beginning of 2008 we had told the employees of Lehman Brothers or AIG that the companies they worked for would fall apart towards the end of Q3 they would have been certain that we were joking.

There is almost no place or context that is free of change, free of innovation and that holds complete certainty about everything. In my personal opinion, such a world does not exist. But, there are people who would rather work in an organized, safe workplace, where the hours are steady and the paycheck comes in regularly. They prefer that to a slightly higher (or even a much higher) income that doesn’t offer financial security.

As opposed to this type of person, others enjoy, get excited by, and are even addicted to, the combination of uncertainty and lack of control over situations. For these people (some of whom definitely would meet the criteria for entrepreneurs) – the security of working in a large and organized company is not at all appealing. Their ability to grow and flourish is expressed best in situations of uncertainty and in total lack of control over events and developments, typical of any field of entrepreneurship.

The main question still remaining is how to function in situations of uncertainty. How does the individual person function in uncertainty, how does this person’s family handle such a situation, how does the department at this person’s place of work handle it or even how does the entire organization?

In situations of uncertainty different people act and behave in different ways. Some are at their best (and we will need to elaborate on this), and some function very poorly. This can be manifest as hesitation, lack of self-confidence, changing decisions hastily, making decisions that were not thought through properly or decisions that were over thought. We can assume though that the way people function in situations of uncertainty can also be changed and that practicing, training, or a more comprehensive early preparation, will significantly improve the results that a private person or manager will achieve.

This suggests a very important question regarding the behavioural repertoire of people, organizations, groups or firms, when faced with situations of uncertainty. If such a repertoire does not exist and there is only a single pattern of operation, then most of the real situations will be handled in the same way. However, in a changing reality, it is best to have the ability to present a changing behavioural system – such a system that enables reaction to most real situations as if they were regular and routine, even if they appear suddenly or at a very low frequency. The most tangible example is from the field of medicine. Patients expect to receive the best and most professional care from their doctors even if the diagnosed illness is very rare and or if the required medical procedure is performed very rarely. This means that a doctor’s behavioural repertoire must include the ability to treat any illness as if it were common, well known, and familiar. Functioning in situations of uncertainty or low frequency must be as professional and effective as if they were totally routine events.

Posted on

חדשות ביראד – אפריל 2018

חוקר/ת יקר/ת,

“עלון חוקרים” חודש אפריל מרכז עבורכם את ה”קולות קוראים” החדשים עם הרשות לחדשנות ועם התעשייה.

נודה באם תקדישו מזמנכם לפתוח אותו ולקרוא את התכנים אשר בו, על מנת לבדוק היתכנות לשת”פ. צוות ביראד עומד לרשותכם בכל שאלה או בקשה.

בהזדמנות זו, חוקרים יקרים, לקראת יום העצמאות למדינת ישראל, אנו יכולים להסתכל בגאווה על ההישגים המחקריים/ האקדמיים שלכם שהצמיחו פיתוחים טכנולוגיים מתקדמים לטובת אוכלוסיית העולם.

מי ייתן ושנת העצמאות השבעים של מדינת ישראל הבאה עלינו לטובה, תהיה שנה של שלום ואחווה, שנה של כבוד הדדי ושוויון, שנה של סובלנות והקשבה, שנה של צמיחה ושגשוג!

חג עצמאות שמח,

ד”ר צביקה בן-פורת

מנכ”ל ביראד

 

Posted on

CogniFiber has been selected to take part in Intel’s Ingenuity Partner Program (Intel IPP)

As part of the program, CogniFiber will be mentored by experts from Intel’s business organizations, will be exposed to state-of-the-art technology, along with an educational infrastructure and local and international events.

CogniFiber has been chosen to participate in the fourth cycle of Intel’s prestigious program for leveraging startups. The program’s framework is based on a demo and POC which is built on defining joint project goals for CogniFiber and Intel. The company will gain mentoring by experts from Intel’s business organizations, will be exposed to state-of-the-art technology, together with an educational infrastructure and local and international events.

Cognifiber is a leader in the field of photonic computing, the emerging technology of the next decades. The primary development of the technology on which the company was founded was done by Dr. Eyal Cohen, who performed a post-doctorate research in the laboratory of Prof. Zeev Zalevsky, from the Faculty of Engineering, in Bar-Ilan university in collaboration with Dr. Mickey London from The Interdisciplinary Center for Neural Computation (ICNC), The Hebrew University of Jerusalem, as an additional advisor. Dr. Eyal Cohen approached the two with a proposal to carry out the research and with Prof. Zalevsky’s extensive experience, promoted the research and its commercialization through BIRAD, Research & Development company Ltd. and the Deputy President of Bar-Ilan university.

Dr. Eyal Cohen together with Prof. Zalevsky and Ms. Keren Levy, who served as a business advisor for the company, co-founded the company. Dr. Eyal Cohen, acts as the leading entrepreneur and company CEO, Prof. Zeev Zalevsky is the company CTO and Keren Levy acts as the company COO.

CogniFiber implements advanced algorithms such as machine learning and deep learning neural networks within unique optic fibers, which enable up to 10,000x acceleration in computation rate, coupled with a staggering 10x-100x reduction in power consumption and heat dissipation, at these computation rates. CogniFiber’s photonic devices will not only revolutionize the world of AI and computing, but will also make AI cheaper, more mobile and more accessible. In-fiber photonic computing devices can deliver a solution for the ever-growing processing needs, they are easy to manufacture, scalable, fault-resistant, and could be connected to any existing communication platform.

Intel’s IPP program is open (every cycle) for about 10 companies and offers them 6-8-months of professional mentoring framework to improve their technology and products, while leveraging on Intel’s technological resources, global presence, and vast network of business connections, in preparation for a successful market penetration. The program is in collaboration with Intel Capital, one of the world’s biggest Venture Capitals, which enables entrepreneurs direct access to this track.

The IPP program, which began operating in 2015, has accompanied about 30 companies, which raised a total of 281 million dollars between them in the past three years. 93% of the companies are still active, and Intel does not demand or take equity or percentages.

With the purchase of Mobileye, Replay, and positioning Intel as a data company, Intel is without a doubt a central player in all emerging and exciting technologies of today’s industry and acts as an excellent source for entrepreneurs who want to accelerate their product or technology.

http://www.Intel.com/ipp

BIRAD:

Birad – Research & Development Company Ltd. the commercializing company of Bar-Ilan University, which promotes innovative technology commercialization, invented by university researchers, encourages scientists to promote their researches and expand them towards industrial and implementational initiatives.

Additional details at the company’s site: www.birad.biz

For additional info regarding CogniFiber: http://www.cognifiber.com

For additional details: Merav Burstein – 052-2229330 – merav@birad.biz

 

 

Posted on

Researchers Invent Nano-Drops That Improve Nearsightedness and Farsightedness

 

Nano-Drops May Offer New Alternative to Current Methods of Vision Correction

Ramat Gan, Israel — A revolutionary, cutting-edge technology, developed by researchers at Bar-Ilan University’s Institute of Nanotechnology and Advanced Materials (BINA), has the potential to provide a new alternative to eyeglasses, contact lenses, and laser correction for refractive errors.

The technology, known as Nano-Drops, was developed by Dr. David Smadja (Ophthalmologist from Shaare Zedek Medical Center), Prof. Zeev Zalevsky, from Bar-Ilan’s Kofkin Faculty of Engineering, and Prof. Jean-Paul Moshe Lellouche, Head of the Department of Chemistry at Bar-Ilan. A related patent on this new invention was recently filed by Birad – Research & Development Company Ltd., the commercializing company of Bar-Ilan University.  Steve Elbaz is a Co-Founder and Chief Business Officer of the new technology.
Nano-Drops achieve their optical effect and correction by locally modifying the corneal refractive index. The magnitude and nature of the optical correction is adjusted by an optical pattern that is stamped onto the superficial layer of the corneal epithelium with a laser source. The shape of the optical pattern can be adjusted for correction of myopia (nearsightedness), hyperopia (farsightedness) or presbyopia (loss of accommodation ability). The laser stamping onto the cornea takes a few milliseconds and enables the nanoparticles to enhance and ‘activate’ this optical pattern by locally changing the refractive index and ultimately modifying the trajectory of light passing through the cornea.

The laser stamping source does not relate to the commonly known ‘laser treatment for visual correction’ that ablates corneal tissue. It is rather a small laser device that can connect to a smartphone and stamp the optical pattern onto the corneal epithelium by placing numerous adjacent pulses in a very speedy and painless fashion.  Tiny corneal spots created by the laser allow synthetic and biocompatible nanoparticles to enter and locally modify the optical power of the eye at the desired correction.

In the future this technology may enable patients to have their vision corrected in the comfort of their own home. To accomplish this, they would open an application on their smartphone to measure their vision, connect the laser source device for stamping the optical pattern at the desired correction, and then apply the Nano-Drops to activate the pattern and provide the desired correction.

Upcoming in-vivo experiments in rabbits will allow the researchers to determine how long the effect of the Nano-Drops will last after the initial application. Meanwhile, this promising technology has been shown, through ex-vivo experiments, to efficiently correct nearly 3 diopters of both myopia and presbyopia in pig eyes.

Posted on

חדשות ביראד – מרץ 2018

חוקר/ת יקר/ה

צוות החוקרים של אוניברסיטת בר-אילן מהווה קבוצה איכותית וערכית בתרומתה לקידום האנושות, בתחומים רבים ומגוונים, החל מביולוגיה ימית, דרך דימות, אופטיקה, מחשוב, תקשורת ואבטחת מידע, מחזור אנרגיה וביופיזיקה, ועד חקר הסרטן, מחלות זקנה, מחשוב ומדעים קוגניטיביים.

מחקרים רבים הנולדים בתוך מעבדות האוניברסיטה מתפתחים לידי מחקרים יישומים בעלי פוטנציאל מסחרי.

תפקידנו הוא לעודד אתכם לקדם את מחקרכם לתחומי המחקר היישומי, ולכן בעלון זה תמצאו רשימת פרויקטים ומיזמים מעניינים לשיתופי פעולה עם האקדמיה. כמו גם דוגמאות של סיפורי הצלחה חדשים של עמיתכם החוקרים.

אני מקווה כי העלונים החודשיים, אתר האינטרנט החדש וצוות ביראד המיומן יסייעו לכם וידרבנו אתכם להגיש בקשות לפרויקטים.

בהצלחה לכולנו!

ד”ר צביקה בן-פורת

מנכ”ל ביראד

Posted on

ContinUse Biometrics one of ten start-ups to take first place in 2018 Prism Awards for breakthrough applications in photonics

Company recognized for its development by Bar-Ilan University engineering professor of a biometric sensing system that detects biomedical parameters from a distance without human contact

Israeli start-up ContinUse Biometrics is among the ten first-place winners of the prestigious 2018 Prism Award (the Oscar of the photonics industry) for the Medical and Health category.  The company is being recognized for its invention of an optical sensing system (sensory camera) in a competition sponsored by Photonics and SPIE Media This is the tenth year that the competition has been held.

“We chose the ten companies that introduced the greatest innovation and creativity in their products and showed impressive data and performance in every possible parameter.  These are inventions that, without a doubt, advance the photonics industry and its prosperity,” noted the organizers of the competition.

ContinUse Biometrics took first place for its laser-based detector and camera that remotely and accurately identify nanoscale movements.  The sensor is aimed at the subject, enabling accurate physiological data to be obtained.

ContinUse Biometrics focuses on developing novel devices for the health field in general and preventive medicine in particular — for use in the home, the vehicle, the workplace and the clinic.  Its products enable ongoing monitoring of vital indicators and patients suffering from chronic diseases such as heart disease, respiratory diseases, and more.

The products developed by ContinUse Biometrics is ideal for senior citizens by virtue of the fact that it transfers medical care from the doctor’s office to the home environment and alerts medical professionals to any change in vital indicators.  The attending physician receives all the readings remotely and provides appropriate medical instructions to the patient. This Telemedicine platform has the potential to minimize visits to clinics and/or hospitalization, while monitoring the patient in his own home in a comfortable, non-contact environment and increased level of service.

The detector is based on the development of Bar-Ilan University engineering professor Zeev Zalevsky, Chief Technology Officer of ContinUse Biometrics. . The detector identifies several groups of physiological parameters including vital signs such as heartbeat,, breathing and blood pressure; allows for listening to heart and breathing sounds (much like a stethoscope); identifies changes in peripheral blood flow patterns; identifies hematologic parameters; identifies people according to their heart tone; and provides muscle and bone measurements including changes in muscle tone and detection of fractures. All measurements are conducted remotely, with no human contact.

The response of medical markets to this development has been most enthusiastic, and the business potential is estimated at hundreds of millions of dollars. In addition, the company plans to activate the sensor in clinics and operating rooms. In this framework, the company will perform several hospital clinical trials over the coming year.

ContinUse Biometrics was founded by CEO Asher Polani with assistance from Bar-Ilan University’s BIRAD Research and Development Company Ltd., which promotes the commercialization of innovative technologies invented by university researchers, and encourages scientists to advance and expand their research with an eye toward industrial applications.

For further information, contact: Merav Burstein, BIRAD Research and Development Company Ltd., 077-3643534, 052-2229330, Merav@birad.biz